Last reviewed · How we verify

NCT06965335: HEBE

Early-Onset Colorectal Cancer: An Observational Retrospective and Prospective Multicenter Study

Recruiting now Last updated 11 May 2025
What this trial tests

trial testing BIOLOGICAL STUDY aiming at describing clinicophatological features of EO-CRC vs SO-CRC in Colo-rectal Cancer in 20 participants. Currently enrolling.

Timeline
17 April 2024
Primary endpoint
31 December 2026
30 June 2027

Quick facts

Lead sponsorNiguarda Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment20
Start date17 April 2024
Primary completion31 December 2026
Estimated completion30 June 2027
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Niguarda Hospital

Who can join

Adults 18 to 40, any sex, with Colo-rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational, retrospective and prospective multicentric Italian study of patients diagnosed with colorectal cancer between age 18-40, aiming at underpinning the biology of vEO-CRC, including colibactin as well as a broader proteo-genomic characterization, to identify potential new therapeutic targets specifically directed to this peculiar subset of patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Colo-rectal Cancer

Currently open trials in the same condition.

Other Niguarda Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06965335.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing